Arrayjet are proud to welcome Dr. Joe Keegan, a globally renowned life science entrepreneur to join as non-executive director
- Posted: 03/08/17
Arrayjet, the inkjet bioprinting solutions provider has recently announced the appointment of Dr Joseph Keegan, US-based biotechnology entrepreneur to join the board of Arrayjet as a non-executive director.
Dr. Keegan brings exceptional depth of experience and knowledge about building successful life science technology companies. He has more than 30 years of experience in life science businesses. As Chief Executive Officer at ForteBio, Inc., he raised $25M, established product development and sales strategies that resulted in an annual revenue growth of 45%, and exited the company through its sale to Pall Corporation. During his nine-year tenure at Molecular Devices Corporation, Dr. Keegan grew the company's revenues from $30M to $200M through internal growth and acquisitions.
In addition to joining Arrayjet, Dr. Keegan currently serves on the Boards of Directors of Courtagen Life Sciences, Carterra, Inc., Halo Laboratories, Inc., Interpace Diagnostics Inc., Labcyte Corporation (as Chairman), Nanomedical Diagnostics, Inc., Unchained Labs, Inc., and the San Francisco Opera. He holds a B.A. in Chemistry from Boston University and a Ph.D. in Physical Chemistry from Stanford University.
Dr Iain McWilliam, CEO of Arrayjet comments, “For us to attract one of the most powerful names in the life sciences industry as a non-executive director speaks volumes for our international reach and development. Joe Keegan has demonstrated success after success in a long and remarkable career and will be an indispensable guide to the Arrayjet team as we move forward. He brings tremendous depth of experience and knowledge about building successful life science technology companies. We are privileged to have Joe Keegan join us and I know his involvement will be transformative for our business at home and overseas."
Commenting on his appointment, Dr Keegan said, “I look forward to working with Iain McWilliam and the Arrayjet team on developing strategies that leverage their high throughput bio-printing technologies to accelerate growth. Moreover, contributing to make the best decisions regarding new product development and commercial execution will be top priorities.”
Arrayjet is supported by investment from the Archangels, the prominent Scottish-based business angel syndicate and the Scottish Investment Bank.
Dr Sarah Hardy, Chief Investment Officer from the organisation comments; “I am delighted by the addition of Joe Keegan to the Arrayjet Board. His very considerable international experience across the life science industry will be of great value to the Company as it continues to grow.”